2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-118410
    L-738167 163212-43-9 98%
    L-738167 is an orally active fibrogen receptor antagonist that prevents the binding of fibrinogen to GP IIb/IIIa. L-738167 can be utilized in thrombus research.
    L-738167
  • HY-118488
    L 640035 77167-93-2 98%
    L 640035 is athromboxaneantagonist.
    L 640035
  • HY-118674
    AK-2-38 122508-12-7 98%
    AK-2-38, a Nifedipine (HY-B0284) analogue, is a calcium channel antagonist. AK-2-38 also has partial agonist effects on isolated guinea pig left atrium.
    AK-2-38
  • HY-118689
    RA-2 1867107-62-7 98%
    RA-2 is a negative-gating modulator of KCa2/3 channels with an IC50 of 17 nM. RA-2 inhibits bradykinin-induced endothelium-derived hyperpolarization (EDH)-type relaxation in U46619-precontracted rings. RA-2 can help to define the physiologic and pathomechanistic roles of KCa2/3 in the vasculature, central nervous system, and during inflammation.
    RA-2
  • HY-118778
    KR-32568 852146-73-7 99.80%
    KR-32568 is a sodium/hydrogen exchanger-1 (NHE-1) inhibitor with an IC50 of 230 nM. KR-32568 has cardioprotective effects.
    KR-32568
  • HY-118779
    Rhazimine 93772-08-8 98%
    Rhazimine is an indole alkaloid that is a dual inhibitor of arachidonic acid metabolism and platelet activating factor-induced platelet aggregation.
    Rhazimine
  • HY-118833
    RAC 109 25360-99-0 98%
    RAC 109 is a local anesthetic. RAC 109 reduces ventricular conduction velocity and myocardial contractility in rabbits in a stereospecific manner (EC50=30 μM).
    RAC 109
  • HY-118938
    Hoquizil hydrochloride 23256-28-2 98%
    Hoquizil hydrochloride is a novel bronchodilator with oral activity, demonstrating phosphodiesterase inhibitory effects and potential for modulation of smooth muscle contraction.
    Hoquizil hydrochloride
  • HY-118991
    KT-1 47487-05-8 98%
    KT-1 is a vasodilator. KT 1 can decrease aortic pressure, renal blood flow, left ventricular enddiastolic pressure and resistances of total peripheral, vertebral, coronary and renal vasculatures and increase aortic blood flow, vertebral blood flow, coronary blood flow, peak positive left ventricular dP/dt and heart rate in anesthetized open-chest dogs. KT-1 can be used for the research of cardiovascular disease.
    KT-1
  • HY-119013
    VPC32183 717110-61-7 98%
    VPC32183 is a competitive antagonist of LPA1 and LPA3 receptors. The activity of VPC32183 can inhibit lipid phosphatase 1 (LPP1), thereby preventing the activation of ERK(1/2) by dioctanoic acid diglyceride (DGPP 8:0). By reducing the expression of LPP1, VPC32183 can further reduce DGPP 8:0-induced ERK(1/2) activation. The effects of VPC32183 suggest that it may have a positive regulatory function in cell signaling processes.
    VPC32183
  • HY-119025
    L 681176 91386-17-3 98%
    L 681176 is an angiotensin-converting enzyme inhibitor that can be isolated from STREPTOMYCES sp. MA 5143a.
    L 681176
  • HY-119038
    ML-7 109376-83-2 98%
    ML-7 is a myosin light chain kinase inhibitor with the activity to inhibit superoxide anion (O(2)(-)) release in human neutrophils. ML-7 can affect the activity of neutrophils independently of myosin light chain kinase. ML-7 inhibits the extracellular O(2)(-) release of stimulated cells, but has no effect on the intracellular O(2)(-) production. ML-7 also strongly inhibits the binding of the intracellular compartment of oxide production to the cell membrane, indicating that it plays a key role in stimulated neutrophils. At the same time, ML-7 protects cardiac function from ischemia/reperfusion injury.
    ML-7
  • HY-119081
    GSK2181236A 1160426-89-0 98%
    GSK2181236A is a NO-insensitive soluble guanylate cyclase (sGC) activator. GSK2181236A can dilate blood vessels, decrease mean arterial pressure and attenuate the development of cardiac hypertrophy. GSK2181236A can be used for the research of cardiovascular disease, such as hypertension.
    GSK2181236A
  • HY-119085
    ACT-281959 1159501-31-1 98%
    ACT-281959 is an orally active prodrug of Selatogrel (HY-109122), a P2Y12 receptor antagonist. ACT-281959 can inhibit platelet aggregation and can be used for the research of cardiovascular disease.
    ACT-281959
  • HY-119092
    Bisaramil 89194-77-4 98%
    Bisaramil is an orally active antiarrhythmic agent. Bisaramil exerts concentration dependent inhibitory effect on PMA-stimulated free radical generation and prolonged the time lag concentration dependently.
    Bisaramil
  • HY-119262
    ABT-866 258526-74-8 98%
    ABT-866 is an α1A-adrenoceptor agonist and an antagonist at the α1B- and α1D-adrenoceptor subtypes. ABT-866 has an EC50 of 0.60 μM for the α1A in the rabbit urethra. ABT-866 has a pA2 value of 5.4 for the α1B in the rat spleen. ABT-866 has a pA2 value of 6.2 for the α1D in the rat aorta. ABT-866 exhibits good urethral selectivity and lower cardiovascular side effects in stress urinary incontinence models. ABT-866 can be used for the research of diseases such as stress urinary incontinence.
    ABT-866
  • HY-119306
    MCC-134 181238-67-5 98%
    MCC-134, a blocker of mitochondrial and opener of surface ATP-sensitive K+ (KATP) channels, abrogates cardioprotective effects of chronic hypoxia. MCC-134 is a vasorelaxing agent.
    MCC-134
  • HY-119379
    Fonsartan free acid 144628-52-4 98%
    Fonsartan (HOE-720) free acid is an orally active angiotensin II receptor (AT1R) antagonist with an IC50 value of 0.48 nM, exhibiting potent antihypertensive activity. Fonsartan free acid dose-dependently inhibits angiotensin II-induced pressor response in rats (ID50 = 0.11 mg/kg) and shows significant long-lasting blood pressure-lowering effects in high-renin animal models. Fonsartan free acid is primarily used in research on hypertension and cardiovascular diseases.
    Fonsartan free acid
  • HY-119544
    Ripisartan 148504-51-2 98%
    Ripisartan (UP-2696) is an angiotensin II receptor antagonist. Ripisartan is orally available. Ripisartan binds to angiotensin II receptors, dilates blood vessels, and lowers blood pressure.
    Ripisartan
  • HY-119545
    PD159790 179598-53-9 98%
    PD159790 is a selective endothelin-converting enzyme-1 (ECE-1) inhibitor, with an EC50 of 28.1 μM.
    PD159790
Cat. No. Product Name / Synonyms Application Reactivity